{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:05:38Z","timestamp":1782486338022,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11886-023-01884-9","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T13:51:49Z","timestamp":1681998709000},"page":"607-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure"],"prefix":"10.1007","volume":"25","author":[{"given":"Wei-Lin","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1749-6976","authenticated-orcid":false,"given":"Bo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"17","key":"1884_CR1","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757\u201380.","journal-title":"J Am Coll Cardiol"},{"key":"1884_CR2","first-page":"1","volume":"231","author":"H Ni","year":"2015","unstructured":"Ni H, Xu J. Recent trends in heart failure-related mortality: United States, 2000\u20132014. NCHS Data Brief. 2015;231:1\u20138.","journal-title":"NCHS Data Brief"},{"issue":"8","key":"1884_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","volume":"6","author":"CW Tsao","year":"2018","unstructured":"Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018;6(8):678\u201385.","journal-title":"JACC Heart Fail"},{"issue":"10","key":"1884_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591\u2013602.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"1884_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5334\/gh.1108","volume":"17","author":"YMF Lim","year":"2022","unstructured":"Lim YMF, Ong SM, Koudstaal S, et al. Trends for readmission and mortality after heart failure hospitalisation in Malaysia, 2007 to 2016. Glob Heart. 2022;17(1):20\u201320.","journal-title":"Glob Heart"},{"issue":"8","key":"1884_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamacardio.2020.7472","volume":"6","author":"MA Agarwal","year":"2021","unstructured":"Agarwal MA, Fonarow GC, Ziaeian B. National trends in heart failure hospitalizations and readmissions from 2010 to 2017. JAMA Cardiol. 2021;6(8):952\u20136.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"1884_CR7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/ehf2.13900","volume":"9","author":"P Leszek","year":"2022","unstructured":"Leszek P, Wa\u015b D, Bartolik K, et al. Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013\u20132019. ESC Heart Fail. 2022;9(3):1553\u201363.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"1884_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12933-022-01526-4","volume":"21","author":"B Liang","year":"2022","unstructured":"Liang B, Gu N. Sodium-glucose co-transporter-2 inhibitors in the treatment of diabetes with heart failure. Cardiovasc Diabetol. 2022;21(1):84.","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"1884_CR9","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1056\/NEJMsa063904","volume":"355","author":"F Murad","year":"2006","unstructured":"Murad F. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med. 2006;355(19):2003\u201311.","journal-title":"N Engl J Med"},{"key":"1884_CR10","doi-asserted-by":"publisher","first-page":"792798","DOI":"10.3389\/fphar.2022.792798","volume":"13","author":"G Numata","year":"2022","unstructured":"Numata G, Takimoto E. Cyclic GMP and PKG signaling in heart failure. Front Pharmacol. 2022;13:792798.","journal-title":"Front Pharmacol"},{"issue":"20","key":"1884_CR11","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"J-P Stasch","year":"2011","unstructured":"Stasch J-P, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263\u201373.","journal-title":"Circulation"},{"key":"1884_CR12","doi-asserted-by":"publisher","first-page":"3617498","DOI":"10.1155\/2021\/3617498","volume":"2021","author":"B Liang","year":"2021","unstructured":"Liang B, Zhu Y-C, Lu J, et al. Effects of traditional Chinese medication-based bioactive compounds on cellular and molecular mechanisms of oxidative stress. Oxid Med Cell Longev. 2021;2021:3617498.","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"1884_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000371491","volume":"51","author":"M Tawa","year":"2014","unstructured":"Tawa M, Shimosato T, Iwasaki H, et al. Effects of peroxynitrite on relaxation through the NO\/sGC\/cGMP pathway in isolated rat iliac arteries. J Vasc Res. 2014;51(6):439\u201346.","journal-title":"J Vasc Res"},{"issue":"1","key":"1884_CR14","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.1038\/s41467-021-25617-0","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu R, Kang Y, Chen L. Activation mechanism of human soluble guanylate cyclase by stimulators and activators. Nat Commun. 2021;12(1):5492.","journal-title":"Nat Commun"},{"issue":"2","key":"1884_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3390\/molecules28020861","volume":"28","author":"G Grze\u015bk","year":"2023","unstructured":"Grze\u015bk G, Witczy\u0144ska A, W\u0119glarz M, et al. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension. Molecules. 2023;28(2):861.","journal-title":"Molecules"},{"issue":"15","key":"1884_CR16","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","volume":"76","author":"M Emdin","year":"2020","unstructured":"Emdin M, Aimo A, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week. J Am Coll Cardiol. 2020;76(15):1795\u2013807.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1884_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11897-010-0045-1","volume":"8","author":"V Mitrovic","year":"2011","unstructured":"Mitrovic V, Jovanovic A, Lehinant S. Soluble guanylate cyclase modulators in heart failure. Curr Heart Fail Rep. 2011;8(1):38\u201344.","journal-title":"Curr Heart Fail Rep"},{"issue":"12","key":"1884_CR18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1177\/0091270008322906","volume":"48","author":"R Frey","year":"2008","unstructured":"Frey R, M\u00fcck W, Unger S, et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58\u20132667) in healthy male volunteers. J Clin Pharmacol. 2008;48(12):1400\u201310.","journal-title":"J Clin Pharmacol"},{"issue":"21","key":"1884_CR19","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1161\/CIRCULATIONAHA.108.800292","volume":"119","author":"H Lapp","year":"2009","unstructured":"Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58\u20132667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009;119(21):2781\u20138.","journal-title":"Circulation"},{"issue":"1","key":"1884_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","volume":"34","author":"E Erdmann","year":"2013","unstructured":"Erdmann E, Semigran MJ, Nieminen MS, et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2013;34(1):57\u201367.","journal-title":"Eur Heart J"},{"issue":"9","key":"1884_CR21","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","volume":"14","author":"M Gheorghiade","year":"2012","unstructured":"Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail. 2012;14(9):1056\u201366.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"1884_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/eurjhf\/hfs071","volume":"14","author":"S Ghio","year":"2012","unstructured":"Ghio S, Bonderman D, Felix SB, et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. Eur J Heart Fail. 2012;14(8):946\u201353.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1884_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","volume":"128","author":"D Bonderman","year":"2013","unstructured":"Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction. Circulation. 2013;128(5):502\u201311.","journal-title":"Circulation"},{"issue":"5","key":"1884_CR24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1378\/chest.14-0106","volume":"146","author":"D Bonderman","year":"2014","unstructured":"Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014;146(5):1274\u201385.","journal-title":"Chest"},{"issue":"23\u201324","key":"1884_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00508-016-1068-8","volume":"128","author":"J Mascherbauer","year":"2016","unstructured":"Mascherbauer J, Gr\u00fcnig E, Halank M, et al. Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction\u202f: Study protocol for a randomized controlled trial. Wien Klin Wochenschr. 2016;128(23\u201324):882\u20139.","journal-title":"Wien Klin Wochenschr"},{"issue":"4","key":"1884_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani H-A, Gali\u00e8 N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340.","journal-title":"N Engl J Med"},{"issue":"22","key":"1884_CR27","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1136\/heartjnl-2015-307832","volume":"101","author":"S Rosenkranz","year":"2015","unstructured":"Rosenkranz S, Ghofrani H-A, Beghetti M, et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015;101(22):1792.","journal-title":"Heart"},{"issue":"4","key":"1884_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, D\u2019Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329.","journal-title":"N Engl J Med"},{"issue":"12","key":"1884_CR29","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","volume":"60","author":"M Follmann","year":"2017","unstructured":"Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem. 2017;60(12):5146\u201361.","journal-title":"J Med Chem"},{"issue":"21","key":"1884_CR30","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, et al. effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314(21):2251\u201362.","journal-title":"JAMA"},{"issue":"9","key":"1884_CR31","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/ejhf.1787","volume":"22","author":"F Kramer","year":"2020","unstructured":"Kramer F, Voss S, Roessig L, et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020;22(9):1675\u201383.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"1884_CR32","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-021-01024-y","volume":"60","author":"H Ruehs","year":"2021","unstructured":"Ruehs H, Klein D, Frei M, et al. Population pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction. Clin Pharmacokinet. 2021;60(11):1407\u201321.","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"1884_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119\u201327.","journal-title":"Eur Heart J"},{"key":"1884_CR34","doi-asserted-by":"crossref","unstructured":"\u2022 Filippatos G, Maggioni AP, Lam CSP, et al. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail. 2017;19(6):782\u201391. SOCRATES-PRESERVED found that vericiguat, in exploratory hypothesis-generating analyses, was associated with clinically important improvements in patients\u2019 health status, as assessed by the Kansas City Cardiomyopathy Questionnaire and EQ-5D.","DOI":"10.1002\/ejhf.800"},{"issue":"2","key":"1884_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","volume":"6","author":"PW Armstrong","year":"2018","unstructured":"Armstrong PW, Roessig L, Patel MJ, et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail. 2018;6(2):96\u2013104.","journal-title":"JACC Heart Fail."},{"issue":"12","key":"1884_CR36","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/ejhf.1664","volume":"21","author":"B Pieske","year":"2019","unstructured":"Pieske B, Patel MJ, Westerhout CM, et al. Baseline features of the VICTORIA (vericiguat global study in subjects with heart failure with reduced ejection fraction) trial. Eur J Heart Fail. 2019;21(12):1596\u2013604.","journal-title":"Eur J Heart Fail"},{"key":"1884_CR37","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u20131893. VICTORIA found that among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo.","DOI":"10.1056\/NEJMoa1915928"},{"issue":"11","key":"1884_CR38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","volume":"8","author":"JA Ezekowitz","year":"2020","unstructured":"Ezekowitz JA, O\u2019Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020;8(11):931\u20139.","journal-title":"JACC Heart Fail."},{"issue":"22","key":"1884_CR39","doi-asserted-by":"publisher","first-page":"e021094","DOI":"10.1161\/JAHA.121.021094","volume":"10","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Mulder H, Lopatin Y, et al. Blood pressure and safety events with Vericiguat in the VICTORIA trial. J Am Heart Assoc. 2021;10(22):e021094.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1884_CR40","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","volume":"6","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Giczewska A, Sliwa K, et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol. 2021;6(6):706\u201312.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1884_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12933-020-01024-5","volume":"19","author":"B Liang","year":"2020","unstructured":"Liang B, Zhao Y-X, Zhang X-X, et al. Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol. 2020;19(1):55.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1884_CR42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ejhf.2471","volume":"24","author":"W Mullens","year":"2022","unstructured":"Mullens W, Martens P, Testani JM, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24(4):603\u201319.","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"1884_CR43","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1161\/CIRCULATIONAHA.121.056797","volume":"144","author":"JA Ezekowitz","year":"2021","unstructured":"Ezekowitz JA, Zheng Y, Cohen-Solal A, et al. Hemoglobin and clinical outcomes in the vericiguat global study in patients with heart failure and reduced ejection fraction (VICTORIA). Circulation. 2021;144(18):1489\u201399.","journal-title":"Circulation"},{"issue":"8","key":"1884_CR44","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/ejhf.2285","volume":"23","author":"P Ponikowski","year":"2021","unstructured":"Ponikowski P, Alemayehu W, Oto A, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. Eur J Heart Fail. 2021;23(8):1300\u201312.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1884_CR45","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ejhf.2468","volume":"24","author":"C Saldarriaga","year":"2022","unstructured":"Saldarriaga C, Atar D, Stebbins A, et al. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. Eur J Heart Fail. 2022;24(5):782\u201390.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"1884_CR46","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ejhf.2221","volume":"23","author":"AA Voors","year":"2021","unstructured":"Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail. 2021;23(8):1313\u201321.","journal-title":"Eur J Heart Fail"},{"key":"1884_CR47","doi-asserted-by":"crossref","unstructured":"\u2022 Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020;324(15):1512\u201321. VITALITY-HFpEF found that among patients with heart failure and preserved ejection fraction and recent decompensation, 24-week treatment with vericiguat at either 15-mg\/day or 10-mg\/day dosages compared with placebo did not improve the physical limitation score of the Kansas City Cardiomyopathy Questionnaire.","DOI":"10.1001\/jama.2020.15922"},{"issue":"5","key":"1884_CR48","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/ejhf.2481","volume":"24","author":"J Butler","year":"2022","unstructured":"Butler J, Spertus JA, Bamber L, et al. Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial. Eur J Heart Fail. 2022;24(5):843\u201350.","journal-title":"Eur J Heart Fail"},{"key":"1884_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ahj.2020.01.009","volume":"222","author":"JE Udelson","year":"2020","unstructured":"Udelson JE, Lewis GD, Shah SJ, et al. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020;222:183\u201390.","journal-title":"Am Heart J"},{"issue":"15","key":"1884_CR50","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1001\/jama.2020.16641","volume":"324","author":"JE Udelson","year":"2020","unstructured":"Udelson JE, Lewis GD, Shah SJ, et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial. JAMA. 2020;324(15):1522\u201331.","journal-title":"JAMA"},{"issue":"11","key":"1884_CR51","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-020-00895-x","volume":"59","author":"M Boettcher","year":"2020","unstructured":"Boettcher M, Gerisch M, Lobmeyer M, et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase i healthy volunteer studies. Clin Pharmacokinet. 2020;59(11):1407\u201318.","journal-title":"Clin Pharmacokinet"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-023-01884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-023-01884-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-023-01884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T10:25:07Z","timestamp":1684232707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-023-01884-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1884"],"URL":"https:\/\/doi.org\/10.1007\/s11886-023-01884-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"12 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}